GSK(GSK) Prnewswire·2025-03-03 10:45Core Viewpoint - GSK plc is facing a class action lawsuit due to allegations of misleading statements regarding the withdrawal of Zantac from the market and the knowledge of its potential cancer-causing ingredient, NDMA [1][2]. Group 1: Allegations and Class Action Details - The class period for the lawsuit is from February 5, 2020, to August 14, 2022 [1]. - Allegations state that GSK misrepresented its reasons for removing Zantac, claiming it acted based on available information and regulatory correspondence, while being aware of NDMA's source for nearly 40 years [1]. - GSK assured investors that there was no causal link between ranitidine therapy and cancer, which was later found to be materially false or misleading [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased GSK shares during the specified period are encouraged to register for the class action by April 7, 2025 [2]. - Registered shareholders will receive updates through portfolio monitoring software regarding the case's progress [2]. - Participation in the case incurs no cost or obligation for shareholders [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies engage in responsible business practices and seeks recovery for investors affected by misleading statements that inflated stock prices [3].